secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2026-10-15T12:46:40+00:00
Accession:  0001601830-26-000128
Event type: other_material
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Recursion prices $200M equity offering, reports Sanofi option milestone and early clinical data
--------------------------------------------------------------------------------

- Recursion priced 61,540,000 Class A shares at $3.25/share for ~$200M gross proceeds; offering expected to close Oct 16, 2026.
- Preliminary Sept 30, 2026 cash, equivalents and restricted cash ~$561M, including ~$86M net ATM proceeds from 23,696,330 shares; runway into 2029.
- Sanofi optioned first collaboration development candidate; triggered $10M milestone, bringing total payments to $144M; Recursion eligible for >$300M more and low double-digit royalties.
- REC-4881 TUPELO Phase 1b/2: 87% of 16 efficacy-evaluable FAP patients had polyp burden reductions, 47% median reduction at week 13; no Grade 4/5 TRAEs.
- REC-1245 DAHLIA Phase 1: 91.7% (11/12) at 45/65 mg achieved disease control at 8 weeks; 45 mg selected for expansion after 65 mg exceeded MTD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/0001601830-26-000128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/rxrx-20261015.htm
  HTML page:      https://secwatch.observer/filing/0001601830-26-000128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer